WNT5A and neoplasm: Promoter hypomethylation in prostate cancer has also been reported to facilitate aberrant expression of Wnt5a affecting tumor malignancy [125], and the up-regulation of Wnt signaling by circulating tumor cells (CTCs) in CRPC patients [126].